CN111417633A - 一种β-内酰胺酶抑制剂的晶型及其制备方法 - Google Patents

一种β-内酰胺酶抑制剂的晶型及其制备方法 Download PDF

Info

Publication number
CN111417633A
CN111417633A CN201880076738.2A CN201880076738A CN111417633A CN 111417633 A CN111417633 A CN 111417633A CN 201880076738 A CN201880076738 A CN 201880076738A CN 111417633 A CN111417633 A CN 111417633A
Authority
CN
China
Prior art keywords
compound
formula
crystalline form
crystal form
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880076738.2A
Other languages
English (en)
Other versions
CN111417633B (zh
Inventor
李程
黄志刚
丁照中
李卫东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QILU ANTIBIOTICS PHARMACEUTICAL CO Ltd
Qilu Pharmaceutical Co Ltd
Original Assignee
Qilu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Pharmaceutical Co Ltd filed Critical Qilu Pharmaceutical Co Ltd
Publication of CN111417633A publication Critical patent/CN111417633A/zh
Application granted granted Critical
Publication of CN111417633B publication Critical patent/CN111417633B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了一种β‑内酰胺酶抑制剂的晶型及其制备方法，还包括所述晶型在制备β‑内酰胺酶抑制剂药物中的应用。(I)

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201880076738.2A 2017-12-01 2018-12-03 一种β-内酰胺酶抑制剂的晶型及其制备方法 Active CN111417633B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711251386 2017-12-01
CN2017112513863 2017-12-01
PCT/CN2018/118864 WO2019105479A1 (zh) 2017-12-01 2018-12-03 一种β-内酰胺酶抑制剂的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN111417633A true CN111417633A (zh) 2020-07-14
CN111417633B CN111417633B (zh) 2022-05-06

Family

ID=66665421

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076738.2A Active CN111417633B (zh) 2017-12-01 2018-12-03 一种β-内酰胺酶抑制剂的晶型及其制备方法

Country Status (7)

Country Link
US (1) US11180501B2 (zh)
EP (1) EP3719020B1 (zh)
JP (1) JP6974614B2 (zh)
CN (1) CN111417633B (zh)
CA (1) CA3084099C (zh)
ES (1) ES2928152T3 (zh)
WO (1) WO2019105479A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113292499B (zh) * 2020-02-24 2024-05-28 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的新制备方法及其中间体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091268A1 (en) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CN104768951A (zh) * 2012-08-25 2015-07-08 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
HUE032491T2 (en) 2010-12-22 2017-09-28 Meiji Seika Pharma Co Ltd An optically active diaza-bicyclooctane derivative and a process for its preparation
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
ES2606059T3 (es) 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
CN104334558A (zh) 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 1,3,4-噁二唑和1,3,4-噻二唑β-内酰胺酶抑制剂
CA2874279C (en) 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
WO2014135931A1 (en) 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
EP2808501A1 (de) 2013-05-27 2014-12-03 Siemens Aktiengesellschaft Verfahren zum Betreiben einer GuD-Kraftwerksanlage
US20160287571A1 (en) 2013-10-30 2016-10-06 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
IN2014MU00195A (zh) 2014-01-21 2015-08-28 Wockhardt Ltd
SG11201810725WA (en) * 2016-06-03 2018-12-28 Medshine Discovery Inc Novel β-lactamase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CN104768951A (zh) * 2012-08-25 2015-07-08 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
WO2014091268A1 (en) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郑斌等: "β-内酰胺类抗生素与β-内酰胺酶抑制剂不同配比复方制剂的体外体内抗菌作用研究", 《海峡药学》 *

Also Published As

Publication number Publication date
EP3719020B1 (en) 2022-09-21
CN111417633B (zh) 2022-05-06
US20200385385A1 (en) 2020-12-10
WO2019105479A1 (zh) 2019-06-06
EP3719020A1 (en) 2020-10-07
EP3719020A4 (en) 2021-08-04
CA3084099A1 (en) 2019-06-06
JP2021504416A (ja) 2021-02-15
US11180501B2 (en) 2021-11-23
JP6974614B2 (ja) 2021-12-01
ES2928152T3 (es) 2022-11-15
CA3084099C (en) 2022-05-17

Similar Documents

Publication Publication Date Title
AU2016327264B2 (en) Salts and solid forms of monobactam antibiotic
EP3337485B1 (en) Crystalline forms of ibrutinib
WO2010139981A2 (en) Processes for preparing crystalline forms
WO2010139979A2 (en) Processes for preparing crystalline forms
CN108137574B (zh) 羟烷基噻二唑衍生物
JP2009516704A (ja) 新規なプリューロムチリン誘導体およびその使用
CN111417633B (zh) 一种β-内酰胺酶抑制剂的晶型及其制备方法
CN107739371B (zh) 一类四氢咔唑类小分子有机化合物及其在制备抗菌药物中的用途及其制备方法
CN102224151A (zh) 新的抗微生物剂
US9085607B2 (en) ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
CN106083994B (zh) 取代的噁唑烷酮水溶性衍生物及其应用
CN112062763A (zh) 羟基吡啶酮并[1,2-b][1,2,5]三氮卓平衍生物及制备和应用
CN108250092B (zh) 对环芳烷-氨基酸衍生物及其制备方法
CN112351986A (zh) 苯并噁唑衍生物的晶体
CN112079836B (zh) 三唑并嘧啶类化合物及其盐、组合物和应用
ES2311391B1 (es) Forma cristalina de moxifloxacino base.
CN109665994B (zh) 青花椒碱衍生物及其作为抗菌药物的用途
JP2018509467A (ja) １，２，５−チアジアゾリジン−１，１−ジオキシドの塩形態、結晶形態及びその調製方法と中間体
Wang et al. Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions
CN106146338B (zh) 含金刚烷基的萘醌类衍生物、其制备方法及应用
WO2023139276A1 (en) Process for preparing crystalline sitagliptin hydrochloride monohydrate
Mane et al. Month 2017 Design and Synthesis of Diverse Pyrrole-2-carboxamide Derivatives as a Potent Antibacterial Agents
CN111196839A (zh) 一种硫链丝菌素衍生物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40022902

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240207

Address after: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province

Patentee after: Qilu Pharmaceutical Co.,Ltd.

Country or region after: China

Patentee after: QILU ANTIBIOTICS PHARMACEUTICAL Co.,Ltd.

Address before: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province

Patentee before: Qilu Pharmaceutical Co.,Ltd.

Country or region before: China